(Q24202885)

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Azithromycin: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Molecular insights into the physiology of the 'thin film' of airway surface liquid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Diffuse panbronchiolitis and cystic fibrosis: East meets West

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Pathogenicity of microbes associated with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Macrolide antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Macrolide antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Macrolide antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Daily versus weekly azithromycin in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002203.PUB4

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

21 January 2018

1 reference

12 December 2020

Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection

1 reference

12 December 2020

Anti-inflammatory activity of macrolides: a new therapeutic potential?

1 reference

12 December 2020

Long-term azithromycin may improve lung function in children with cystic fibrosis

1 reference

12 December 2020

Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis.

1 reference

12 December 2020

The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro

1 reference

12 December 2020

Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils

1 reference

12 December 2020

Therapeutic possibilities for diffuse panbronchiolitis

1 reference

12 December 2020

Autoantibodies against bactericidal/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin

1 reference

12 December 2020